Antimicrobial activity of DC-159a, a new fluoroquinolone, against 1,149 recently collected clinical isolates

Página do item simplificado
dc.contributor.authorJones, Ronald N.
dc.contributor.authorFritsche, Thomas R.
dc.contributor.authorSader, Helio S. [UNIFESP]
dc.contributor.institutionJMI Labs
dc.contributor.institutionTufts Univ
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.date.accessioned2016-01-24T13:51:42Z
dc.date.available2016-01-24T13:51:42Z
dc.date.issued2008-10-01
dc.description.abstractThe activity of DC-159a, a novel orally administered fluorinated quinolone, was evaluated by reference broth microdilution or agar dilution methods against 1,149 recently collected clinical isolates from five continents. Against pathogens associated with community-acquired respiratory tract infections (CA-RTIs), the MIC(90)s were 0.12 mu g/ml for Streptococcus pneumoniae, 0.015 to 0.03 mu g/ml for Haemophilus influenzae, 0.03 mu g/ml for Moraxella catarrhalis, and 0.12 mu g/ml for beta-hemolytic streptococci. Similarly, DC-59a was potent against various types of staphylococci (MIC90 range, 0.03 to 2 mu g/ml), Enterococcus faecalis (MIC90, 4 mu g/ml), wild-type isolates of the family Enterobacteriaceae (MIC90 range, 0.06 to 2 mu g/ml), wild-type Pseudomonas aeruginosa (MIC90, 2 mu g/ml), and Acinetobacter spp. (MIC90, 0.12 mu g/ml). Fluoroquinolone-nonsusceptible organism subsets usually had elevated DC-159a MICs, but the MICs were often two- to fourfold lower than those of levofloxacin and moxifloxacin. in conclusion, DC-159a appears to possess a balanced broad spectrum of activity that exceeds the activities of the currently marketed fluoroquinolones, especially against pathogens that cause CA-RTIs.en
dc.description.affiliationJMI Labs, N Liberty, IA 52317 USA
dc.description.affiliationTufts Univ, Sch Med, Boston, MA 02111 USA
dc.description.affiliationUniversidade Federal de São Paulo, São Paulo, Brazil
dc.description.affiliationUnifespUniversidade Federal de São Paulo, São Paulo, Brazil
dc.description.sourceWeb of Science
dc.description.sponsorshipDaiichi Pharmaceutical Co., Ltd.
dc.format.extent3763-3775
dc.identifierhttp://dx.doi.org/10.1128/AAC.00294-08
dc.identifier.citationAntimicrobial Agents and Chemotherapy. Washington: Amer Soc Microbiology, v. 52, n. 10, p. 3763-3775, 2008.
dc.identifier.doi10.1128/AAC.00294-08
dc.identifier.fileWOS000259480800039.pdf
dc.identifier.issn0066-4804
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/30921
dc.identifier.wosWOS:000259480800039
dc.language.isoeng
dc.publisherAmer Soc Microbiology
dc.relation.ispartofAntimicrobial Agents and Chemotherapy
dc.rightsinfo:eu-repo/semantics/openAccess
dc.titleAntimicrobial activity of DC-159a, a new fluoroquinolone, against 1,149 recently collected clinical isolatesen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
WOS000259480800039.pdf
Tamanho:
82.22 KB
Formato:
Adobe Portable Document Format
Descrição:
Baixar
Coleções
EPM - Artigos